Published in Clin Colorectal Cancer on October 01, 2009
Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer. Oncotarget (2015) 0.79
Validation of the Japanese version of HFS-14, a disease-specific quality of life scale for patients suffering from hand-foot syndrome. Support Care Cancer (2015) 0.78
Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment. Ann Surg Oncol (2011) 0.77
Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report. Pan Afr Med J (2015) 0.75
Methyl Sartortuoate Inhibits Colon Cancer Cell Growth by Inducing Apoptosis and G2/M-Phase Arrest. Int J Mol Sci (2015) 0.75
First Case of Foot Drop Associated with Capecitabine in a Patient with Thymidylate Synthase Polymorphism. Cureus (2017) 0.75
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. BMJ Case Rep (2014) 0.75
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP (2008) 2.39
Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP (2009) 1.57
Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol (2009) 1.55
Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer (2009) 1.44
Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOP (2009) 1.43
Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions. JOP (2014) 1.39
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 1.30
Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol (2007) 1.29
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29
Pancreatic neoplasm in 2011: an update. JOP (2011) 1.28
Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs (2010) 1.18
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs (2006) 1.17
Cancers of the appendix: review of the literatures. ISRN Oncol (2011) 1.07
Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP (2007) 1.06
Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs (2010) 1.04
Primary squamous cell carcinoma of the liver. J Gastrointestin Liver Dis (2009) 1.03
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs (2009) 1.02
Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.02
Advancements in the management of pancreatic cancer: 2013. JOP (2013) 1.02
Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP (2007) 1.00
Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00
Capecitabine and hand-foot syndrome. Expert Opin Drug Saf (2010) 0.99
Gastrointestinal stromal tumors of the pancreas. JOP (2010) 0.98
Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol (2010) 0.96
IGF system in cancer: from bench to clinic. Anticancer Drugs (2011) 0.96
Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP (2011) 0.96
Supportive and palliative care of pancreatic cancer. JOP (2007) 0.95
Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. JOP (2008) 0.93
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP (2007) 0.93
FOLFIRINOX: from the ACCORD study to 2014. JOP (2014) 0.91
Pulmonary thromboembolism in AIDS patient with chronic venous insufficiency, pulmonary tuberculosis and breast cancer: a case report and pathophysiology review. Rev Inst Med Trop Sao Paulo (2006) 0.90
Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res (2010) 0.89
Pulmonary toxicity associated with gemcitabine. JOP (2010) 0.89
Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer (2011) 0.89
Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs (2011) 0.89
Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP (2007) 0.89
Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol (2010) 0.88
Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol (2011) 0.87
Expectoration of a lung metastasis in a patient with colorectal carcinoma. Clin Colorectal Cancer (2008) 0.87
Medullary carcinoma of the colon: a case series and review of the literature. In Vivo (2014) 0.87
Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs (2009) 0.87
Early detection of pancreatic cancer. JOP (2012) 0.87
Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP (2009) 0.87
Update on novel therapies for pancreatic neuroendocrine tumors. JOP (2012) 0.86
Quality of life in patients with pancreatic cancer. JOP (2012) 0.86
Gemcitabine-induced pulmonary toxicity. Anticancer Res (2012) 0.86
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP (2013) 0.86
Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP (2008) 0.85
Secondary tumors of the pancreas: a case series. Anticancer Res (2012) 0.85
Pancreatic adenocarcinoma with supraclavicular lymph node metastasis: is this the Virchow's node? JOP (2011) 0.85
Pancreatic neuroendocrine tumors: entering a new era. JOP (2012) 0.85
Nutritional status of patients with locally advanced pancreatic cancer: a pilot study. Support Care Cancer (2010) 0.85
Management of borderline resectable pancreatic adenocarcinoma. JOP (2012) 0.84
Metastatic cervical carcinoma to the thyroid gland: a case report and review of the literature. Yale J Biol Med (2006) 0.84
Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev (2008) 0.84
Cutaneous metastasis in a patient with pancreatic cancer. JOP (2011) 0.84
Advancements in the management of pancreatic cancer. JOP (2009) 0.83
Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. JOP (2013) 0.83
Adjuvant therapy for pancreatic cancer. JOP (2014) 0.83
PARP-inhibitors in BRCA-associated pancreatic cancer. JOP (2014) 0.83
Diabetes and pancreatic cancer. JOP (2014) 0.83
Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.83
First-line treatment for advanced pancreatic cancer. JOP (2013) 0.83
Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007. JOP (2007) 0.82
Locally advanced pancreatic adenocarcinoma: update and progress. JOP (2012) 0.82
The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver (2010) 0.82
Biomarkers in neuroendocrine tumors. JOP (2013) 0.82
Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer. JOP (2009) 0.82
Role of anticoagulation in the management of pancreatic cancer. JOP (2009) 0.82
Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Ther Adv Med Oncol (2012) 0.82
Mitomycin-induced interstitial pneumonitis in a patient with BRCA2 associated metastatic pancreatic carcinoma. JOP (2010) 0.81
Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? Clin Colorectal Cancer (2009) 0.81
Advancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015). JOP (2015) 0.81
KRAS in pancreatic cancer. JOP (2014) 0.81
Elderly patients with pancreatic cancer. JOP (2014) 0.81
Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors. JOP (2014) 0.81
Metastatic pancreatic cancer: the dilemma of quality vs. quantity of life. JOP (2013) 0.81
Novel treatment approaches for locally advanced pancreatic cancer. JOP (2014) 0.81
Post-pancreaticoduodenectomy hemorrhage of unusual origin: treatment with endovascular embolization and the value of preoperative CT angiography. J Radiol Case Rep (2013) 0.81
Adjuvant therapy of pancreatic cancer. JOP (2013) 0.80
Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP (2011) 0.80
Screening and detection of pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP (2011) 0.80
Risk determination for pancreatic cancer. JOP (2014) 0.80